• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.

作者信息

Tendas Andrea, Lissia Maria Felicita, Piccioni Daniela, Tirimbelli Liliana, Scaramucci Laura, Giovannini Marco, Dentamaro Teresa, Perrotti Alessio, de Fabritiis Paolo, Niscola Pasquale

机构信息

Hematology Unit and Department of Pharmacy Services, Sant'Eugenio Hospital, Rome, Italy.

出版信息

Support Care Cancer. 2015 Feb;23(2):303-5. doi: 10.1007/s00520-014-2502-y. Epub 2014 Nov 5.

DOI:10.1007/s00520-014-2502-y
PMID:25370894
Abstract
摘要

相似文献

1
Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.门诊骨髓增生异常综合征及相关疾病患者在阿扎胞苷给药方案依从性方面的障碍。
Support Care Cancer. 2015 Feb;23(2):303-5. doi: 10.1007/s00520-014-2502-y. Epub 2014 Nov 5.
2
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.中危骨髓增生异常综合征预后的优化及阿扎胞苷的疗效
Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.
3
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.阿扎胞苷用于80岁以上急性髓系白血病或骨髓增生异常综合征患者：115例患者的报告
Br J Haematol. 2020 Aug;190(3):461-464. doi: 10.1111/bjh.16680. Epub 2020 May 11.
4
Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
Br J Haematol. 2020 May;189(4):e144-e147. doi: 10.1111/bjh.16565. Epub 2020 Mar 4.
5
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.5’-阿扎胞苷治疗非霍奇金淋巴瘤治疗相关骨髓增生异常综合征。
Leuk Res. 2011 Oct;35(10):1409-11. doi: 10.1016/j.leukres.2011.05.030. Epub 2011 Jun 15.
6
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.阿扎胞苷治疗的骨髓增生异常综合征患者循环原始粒细胞的预后价值
Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3.
7
Azacitidine Use for Myeloid Neoplasms.阿扎胞苷在髓系肿瘤中的应用。
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e147-e155. doi: 10.1016/j.clml.2018.02.005. Epub 2018 Feb 8.
8
5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.5-氮杂胞苷治疗伴有3号染色体倒位的骨髓增生异常综合征
Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4.
9
[The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):789-91.
10
Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.骨髓增生异常综合征的治疗：阿扎胞苷治疗经验引发的问题
J Clin Oncol. 2002 May 15;20(10):2415-6. doi: 10.1200/JCO.2002.20.10.2415.

引用本文的文献

1
Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.地西他滨/西扎珠苷在加拿大治疗骨髓增生异常综合征和慢性粒单核细胞白血病中的应用
Curr Oncol. 2023 Aug 30;30(9):8005-8018. doi: 10.3390/curroncol30090581.
2
Oral hypomethylating agents: beyond convenience in MDS.口服低甲基化药物：在 MDS 中不仅仅是方便。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):439-447. doi: 10.1182/hematology.2021000278.
3
Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation.

本文引用的文献

1
Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.阿扎胞苷治疗慢性粒单核细胞白血病：一种有效且可管理的方法。
Mediterr J Hematol Infect Dis. 2014 Feb 16;6(1):e2014020. doi: 10.4084/MJHID.2014.020. eCollection 2014.
2
Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.根据国际预后评分系统（IPSS）细胞遗传学特征，阿扎胞苷治疗骨髓增生异常综合征的真实生活经验。
Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28.
3
Managing myelodysplastic syndromes in very old patients: a teaching case report.
通过挽救性地西他滨桥接异基因移植治疗阿扎胞苷治疗失败的骨髓增生异常综合征后难治性急性髓系白血病的长期反应
Blood Res. 2019 Dec;54(4):288-290. doi: 10.5045/br.2019.54.4.288. Epub 2019 Dec 20.
4
Azacitidine in outpatient treatment - single center experience.阿扎胞苷门诊治疗——单中心经验
Contemp Oncol (Pozn). 2015;19(6):467-70. doi: 10.5114/wo.2015.56653. Epub 2016 Jan 13.
非常老的患者骨髓增生异常综合征的管理：一个教学病例报告。
Clin Interv Aging. 2013;8:391-4. doi: 10.2147/CIA.S39536. Epub 2013 Apr 11.
4
Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS.高危 MDS 中 5 天阿扎胞苷剂量强化方案的疗效和耐受性。
Ann Hematol. 2013 Sep;92(9):1201-6. doi: 10.1007/s00277-013-1762-9. Epub 2013 Apr 21.
5
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.阿扎胞苷治疗停药后反应迅速丧失：高危骨髓增生异常综合征或慢性粒单核细胞白血病患者的病例系列研究。
Eur J Haematol. 2013 Apr;90(4):345-8. doi: 10.1111/ejh.12079. Epub 2013 Feb 28.
6
Transfusions at home in patients with myelodysplastic syndromes.在家中为骨髓增生异常综合征患者输血。
Leuk Res. 2012 Jun;36(6):684-8. doi: 10.1016/j.leukres.2012.01.010. Epub 2012 Feb 14.
7
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
Leuk Res. 2012 Jan;36(1):e15-7. doi: 10.1016/j.leukres.2011.08.010. Epub 2011 Sep 9.
8
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.持续的阿扎胞苷治疗超过首次缓解时间可改善高危骨髓增生异常综合征患者的缓解质量。
Cancer. 2011 Jun 15;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10.
9
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.阿扎胞苷与常规治疗方案在老年（≥75 岁）高危骨髓增生异常综合征患者中的疗效比较。
Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6.
10
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.阿扎胞苷三种不同给药方案治疗骨髓增生异常综合征患者的血液学反应
J Clin Oncol. 2009 Apr 10;27(11):1850-6. doi: 10.1200/JCO.2008.17.1058. Epub 2009 Mar 2.